U.S. Stock Market Midday Update
Mustang Bio rose 11.81%, with increased trading volume. Based on recent key news:
<ol>
<li>
On August 4, KemPharm had a block trade at a discount of 11.08%, with 285,000 shares traded, totaling 2.9954 million yuan, and the stock price increased by 1.2%.
</li>
<li>
On July 31, Microchip Technology had a block trade at a discount of 17.58%, with 150,000 shares traded, and the stock price increased by 0.27%.
</li>
<li>
On July 29, Microchip Technology had a block trade at a discount of 20.25%, with 1.8994 million shares traded.
</li>
</ol>
Stocks with High Trading Volume in the Industry
Gilead Sciences rose 8.65%, with a trading volume of 482 million USD. Based on recent important news:
<ol>
<li>
On August 8, Gilead Sciences released its Q2 2025 financial report, with product sales increasing by 4% year-on-year to 6.9 billion USD, Biktarvy sales increasing by 9% year-on-year to 3.5 billion USD, and Veklury sales increasing by 35% year-on-year to 653 million USD, with the stock price rising by 5.92%.
</li>
<li>
On August 8, the company raised its full-year revenue and earnings guidance, expecting adjusted earnings per share to be between 7.95 and 8.25 USD, up from the previous range of 7.7 to 8.1 USD, with market expectations at 8.01 USD per share, and the stock price rose 2.9% in pre-market trading.
</li>
<li>
On August 8, Wall Street analysts unanimously recommended &#34;Buy,&#34; with 21 &#34;Strong Buy&#34; or &#34;Buy&#34; ratings, 9 &#34;Hold&#34; ratings, and no &#34;Sell&#34; or &#34;Strong Sell&#34; ratings, with a price target of 120 USD, 8.1% higher than the last closing price.
</li>
</ol>
Forte Pharmaceuticals fell 1.61%, with increased trading volume. Based on recent key news:
<ol>
<li>
On August 5, Forte Pharmaceuticals' target price was lowered to 500 yuan, putting pressure on the stock price, which fell by 1.61%.
</li>
<li>
On August 6, VX-993 did not meet the primary endpoint in Phase II trials, leading to negative market reactions.
</li>
<li>
On August 5, Stifel lowered the target price for Forte Pharmaceuticals to 455 USD, affecting market confidence.
</li>
</ol>
Natera rose 14.49%, with increased trading volume. Based on recent important news:
<ol>
<li>
On August 8, Natera released its Q2 financial report, with record revenue, prompting an upward revision of full-year revenue and gross margin guidance, and the stock price rose by 14.49%.
</li>
<li>
On August 8, BTIG, Bernstein, and JP Morgan raised their target price for Natera, boosting market confidence.
</li>
<li>
On August 7, the new product Fetal Focus was launched, expanding the market and enhancing investor expectations.
</li>
</ol>
Stocks with High Market Capitalization in the Industry
AbbVie fell 0.77%, with increased trading volume. Based on recent key news:
<ol>
<li>
On August 5th, AbbVie raised its full-year guidance, but the market is skeptical about the sustainability of growth and competitive pressures, leading to a decline in stock price.
</li>
<li>
On August 5th, AbbVie acquired the American mental disorder drug manufacturer Gilgamesh Pharmaceuticals, with mixed market reactions.
</li>
<li>
On August 6th, analysts believe AbbVie is not the best investment choice at present, affecting investor confidence
</li>
</ol>

MBIO

Mustang Bio rose 11.81%; Gilead Sciences rose 8.65%, with a trading volume of USD 482 million; Fortress Biotech fell 1.61%, with a trading volume of USD 269 million; Natera rose 14.49%, with a trading volume of USD 210 million; AbbVie fell 0.77%, with a market capitalization of USD 348.5 billion

U.S. stock market update: Mustang Bio up 11.81%